We are live on ! Find out more
EVGN icon

Evogene

18 hedge funds and large institutions have $50.1M invested in Evogene in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

4% more capital invested

Capital invested by funds: $48.4M → $50.1M (+$1.76M)

0.05% more ownership

Funds ownership: 2.94%2.99% (+0.05%)

0% more funds holding

Funds holding: 1818 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
18
Holders Change
Holders Change %
0%
% of All Funds
0.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
5
Reduced
3
Closed
1
Calls
Puts
Net Calls
Net Calls Change

EVGN Hedge Fund Activity: Q3 2016 in Review

18 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2016, worth a combined $50.1M — up 3.6% from $48.4M a quarter earlier.

Fund positioning in EVGN was balanced in Q3 2016: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 3 trimmed.

The largest buyer was UBS Group, adding an estimated $502K. The largest seller was Wellington Management Group, cutting an estimated $179K.

  • 18 institutional investors held Evogene (EVGN) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $50.1M of Evogene stock for Q3 2016, up 3.6% quarter-over-quarter.
  • 1 fund opened new Evogene positions in Q3 2016 and 1 closed out, a net change of 0 holders.
  • The largest Evogene buyer in Q3 2016 was UBS Group, an estimated $502K added.
  • The largest Evogene seller in Q3 2016 was Wellington Management Group, an estimated $179K sold.

Based on aggregated 13F filings for Q3 2016.